---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095744"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:45:41.487545+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q2 net loss $29.9M; expands ADI-001 into three more autoimmune indications

## Summary
- Net loss $29.9M ($0.33/share) vs $32.4M ($0.75) in Q2 2023; cash $224.1M, sufficient into H2 2026.
- FDA cleared IND for ADI-001 in SLE, SSc, AAV; Fast Track for LN; enrollment starts Q3 2024 with data H1 2025.
- FDA cleared IND for ADI-270 in RCC with Fast Track Designation; Phase 1 to start Q4 2024, data H1 2025.
- R&D expenses $25.9M, down from $28.4M; G&A $6.9M, up from $6.5M.
- MCL enrollment ongoing in ADI-001 Phase 1 GLEAN study; clinical update Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-095744
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024095744/0000950170-24-095744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024095744/acet-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095744
- JSON: https://secwatch.observer/filing/0000950170-24-095744.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.